Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 30, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

FDA Requests Data from Clovis for Rociletinib NDA in NSCLC

 

FDA has requested additional clinical data from Clovis Oncology Inc., for the agency’s efficacy analysis of the 500mg and 625mg BID dose patient groups for rociletinib. Clovis said it would provide the information in a major amendment to the FDA.

The agency said that its efficacy analysis would focus solely on confirmed responses. The company’s New Drug Application contained immature data sets based on both unconfirmed response rates and confirmed response rates, according to Clovis.

The updated results contain a lower-than-expected rate of confirmed responses to the drug.

Rociletinib is a novel, oral, targeted covalent mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M. Data from both the single-arm TIGER-X and TIGER-2 clinical trials served as the basis for the U.S. and E.U. regulatory submissions for the treatment of advanced mutant EGFR T790M-positive lung cancer.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter